EMA
safety_alert
· 2016-12-02
PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C
Summary
The EMA’s Pharmacovigilance Risk Assessment Committee warns that hepatitis B re-activation can occur in patients with past or current hepatitis B infection trea…
Upgrade for the full analysis, importance score, and drug timeline.